ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine & Initial Data from Phase 1b FORWARD...
September 17 2019 - 5:30AM
Business Wire
Conference Call to be Held at 8 a.m. ET on Monday, September
30
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that full data and additional exploratory analyses
from the Phase 3 FORWARD I study evaluating mirvetuximab
soravtansine compared to chemotherapy in women with folate receptor
alpha (FRα)-positive, platinum-resistant ovarian cancer will be
presented during an oral presentation at the European Society for
Medical Oncology (ESMO) Congress to be held from September 27 to
October 1, 2019 in Barcelona, Spain. Initial safety and overall
response rate data from the Phase 1b FORWARD II triplet study
evaluating mirvetuximab in combination with carboplatin and
Avastin® (bevacizumab) in patients with recurrent
platinum-sensitive ovarian cancer will also be featured in a poster
at the congress.
Oral Presentation Details
- Title: “FORWARD I (GOG 3011): A Phase III study of
mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting
antibody-drug conjugate (ADC), versus chemotherapy in patients
(pts) with platinum-resistant ovarian cancer (PROC)” (Abstract
#992O)
- Date: September 29, 2019
- Time: 8:30 a.m. CEST/2:30 a.m. EDT
- Lead Author: Kathleen Moore M.D., University of Oklahoma
Health Sciences Center, Oklahoma City, OK
Poster Details
- Title: “Mirvetuximab soravtansine, a folate receptor
alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination
with carboplatin and bevacizumab: Initial results from a Phase 1b
study in patients with ovarian cancer” (Abstract #1028P)
- Date: September 29, 2019
- Time: 12:00 p.m. CEST/6:00 a.m. EDT
- Lead Author: David M. O’Malley M.D., James Cancer Center
and The Ohio State University Wexner Medical Center, Columbus,
OH
Additional information and full abstracts can be found at
www.esmo.org.
CONFERENCE CALL INFORMATION ImmunoGen will hold a
conference call at 8 a.m. ET on Monday, September 30, 2019. Dial-in
details to follow.
ABOUT MIRVETUXIMAB SORAVTANSINE Mirvetuximab soravtansine
(IMGN853) is the first folate receptor alpha (FRα)-targeting ADC.
It uses a humanized FRα-binding antibody to target the ADC
specifically to FRα-expressing cancer cells and a potent anti-tumor
agent, DM4, to kill the targeted cancer cells.
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates to improve outcomes for
cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
AVASTIN® is a registered trademark of Genentech, Inc.
This press release includes forward-looking statements based on
management's current expectations. These statements include, but
are not limited to, ImmunoGen’s expectations related to: the
occurrence, timing, and outcome of potential pre-clinical,
clinical, and regulatory events related to the Company’s product
candidates. For these statements, ImmunoGen claims the protection
of the safe harbor for forward-looking statements provided by the
Private Securities Litigation Reform Act of 1995. Various factors
could cause ImmunoGen’s actual results to differ materially from
those discussed or implied in the forward-looking statements, and
you are cautioned not to place undue reliance on these
forward-looking statements, which are current only as of the date
of this release. Factors that could cause future results to differ
materially from such expectations include, but are not limited to:
the timing and results of communications with FDA, risks and
uncertainties related to the execution of the restructuring of the
Company’s operations, the Company’s ability to control future
spending to enable it to fund its remaining operations through the
release of top-line results from the upcoming mirvetuximab pivotal
study, as well as the risks and uncertainties inherent in the
Company’s development programs, including clinical studies and
regulatory processes, their timings and results. A review of these
risks can be found in ImmunoGen’s Annual Report on Form 10-K for
the year ended December 31, 2018 and other reports filed with the
Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190917005315/en/
INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O’Konek
781-895-0600 courtney.okonek@immunogen.com OR FTI Consulting
Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024